CD4 News and Research

RSS

Tibotec Virco Virology BVBA acquires Ground Zero Software's LAB TRACKER HIV EMR system

Tibotec Virco Virology BVBA today announced the acquisition of LAB TRACKER(TM) HIV, a customized electronic medical record (EMR) system, from the company Ground Zero Software. LAB TRACKER(TM) HIV is a full-service, scalable software platform designed to meet the complex disease-management needs of health care providers who are treating people living with HIV/AIDS.

15 Dec 2009

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

15 Dec 2009

Clinical trial of 2009 H1N1 influenza vaccine

HIV-infected adults currently are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, will enroll approximately 240 men and women between the ages of 18 and 64.

13 Dec 2009

ARTs safe without routine lab tests, Lancet study finds

A Lancet study published online Tuesday validates the safety of administering first-line antiretroviral therapy (ART) to patients with HIV without routine toxicity and efficacy lab tests, "[b]ut tests of immune-system function might still be a good idea to monitor the progression of the disease and guide the second year of treatment," HealthDay/U.S. News & World Report reports. Patients in Africa "often receive [HIV] drug treatment ... without routine laboratory monitoring," according to the article.

10 Dec 2009

Washington Post, New York Times examine PEPFAR

The Washington Post examines the Obama administration's goal "to get the 'emergency' out of the President's Emergency Plan for AIDS Relief" and integrate HIV/AIDS programs more into the health infrastructure of recipient countries. A five-year strategy for PEPFAR was released last week.

9 Dec 2009

Leaders respond to World AIDS Day; South Africa to expand HIV treatment program

Marking World AIDS Day on Tuesday, U.N. Secretary General Ban Ki-Moon "warned ... that new infections are outpacing the gains from treating people with the HIV virus" and that discrimination against HIV-positive people remains "widespread," the Associated Press reports.

2 Dec 2009

AHF lauds WHO for its crucial HIV treatment recommendations

On the eve of World AIDS Day 2009, AIDS Healthcare Foundation (AHF) praised the World Health Organization (WHO) for its new HIV treatment recommendations which include starting lifesaving antiretroviral treatment (ART) earlier (at a t-cell count of <350 cells/mm3 instead of <200) for all HIV-positive adults and adolescents and earlier treatment initiation for HIV-positive pregnant women who should now begin treatment at 14 weeks into pregnancy, rather than 28 weeks as previously recommended, and continue until the end of breastfeeding.

1 Dec 2009

WHO issues new HIV/AIDS treatment guidelines

The WHO on Monday issued new recommendations that patients living with HIV/AIDS begin receiving antiretrovirals (ARVs) earlier than current HIV treatment advice suggests, the Associated Press reports

1 Dec 2009

Reductionist model provides new insights on HIV infection

A major obstacle to HIV research is the virus's exquisite specialisation for its human host - meaning that scientists' traditional tools, like the humble lab mouse, can deliver only limited information. Now, a team of researchers writing in BioMed Central's open access Journal of Biology have made an ingenious assault on this problem by creating a mouse that has key features of HIV infection without being infected with HIV.

1 Dec 2009

Obese, HIV patients do not respond to antiretroviral therapy, says new study

The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.

25 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Data from Phase 1 safety study of SB-728-T announced

Sangamo BioSciences, Inc. announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.

19 Nov 2009

CD4 Initiative selects Zyomyx's CD4 POC technology as best for measuring CD4 T-cell count in HIV/AIDS patients

Zyomyx, Inc., a leader in chip-based bioanalysis technologies, today announced that its readerless CD4 point-of-care (POC) technology was selected by Imperial College London's CD4 Initiative as the best-performing POC test method for measuring CD4 T-cell count in HIV/AIDS patients. Zyomyx's CD4 assay is now the only remaining POC product being supported by the CD4 Initiative.

17 Nov 2009

Healthy adults may have better immunity to 2009 H1N1 influenza virus, says study

A new study shows that molecular similarities exist between the 2009 H1N1 influenza virus and other strains of seasonal H1N1 virus that have been circulating in the population since 1988. These results suggest that healthy adults may have a level of protective immune memory that can blunt the severity of infection caused by the 2009 H1N1 influenza virus.

17 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Replenish+ delays the progression of AIDS in HIV-infected patients not receiving ART

Data presented today from a 310 patient, 52 week, double-blind, controlled clinical trial demonstrates that a micronutrient supplement, Replenish+™ delays the progression of AIDS in HIV-infected patients not receiving antiretroviral treatment (ART).

31 Oct 2009

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sangamo BioSciences, Inc. announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells.

29 Oct 2009

Sperm can transmit HIV to macrophages and dendritic cells

Sperm, and not just the fluid it bathes in, can transmit HIV to macrophages, T cells, and dendritic cells (DCs), report a team led by Ana Ceballos at the University of Buenos Aires in Argentina.

27 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

21 Oct 2009

CD4 News and Research

Tibotec Virco Virology BVBA acquires Ground Zero Software's LAB TRACKER HIV EMR system

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

Clinical trial of 2009 H1N1 influenza vaccine

ARTs safe without routine lab tests, Lancet study finds

Washington Post, New York Times examine PEPFAR

Leaders respond to World AIDS Day; South Africa to expand HIV treatment program

AHF lauds WHO for its crucial HIV treatment recommendations

WHO issues new HIV/AIDS treatment guidelines

Reductionist model provides new insights on HIV infection

Obese, HIV patients do not respond to antiretroviral therapy, says new study

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Data from Phase 1 safety study of SB-728-T announced

CD4 Initiative selects Zyomyx's CD4 POC technology as best for measuring CD4 T-cell count in HIV/AIDS patients

Healthy adults may have better immunity to 2009 H1N1 influenza virus, says study

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Replenish+ delays the progression of AIDS in HIV-infected patients not receiving ART

Sangamo BioSciences awarded a grant to develop zinc finger nuclease-based stem cell therapy for AIDS

Sperm can transmit HIV to macrophages and dendritic cells

Anti-viral drug development programs progress successfully, reports NanoViricides

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News